Market Overview

The global interventional cardiology market is anticipated to reach USD 25.93 billion by 2020 growing at a CAGR of 7.9% during the forecasting period, 2020-2028. Interventional cardiology is the cardiology which deals with the catheter-based treatment of structural heart diseases. It helps in the avoidance of scars and pain, and long post-operative recovery. Factors such as the rising geriatric population due to higher life expectancy and increasing clinical evidence of the effectiveness of advanced interventional cardiac devices are some of the major drivers for the interventional cardiology market

Key Findings

The global interventional cardiology market is segmented into type, system, end-user, and geography.

The type segment is segmented into Balloons, Stents, Catheters, Plaque Modification Devices, Hemodynamic Flow Alteration Devices, and Others

System segment is segmented into Fractional Flow Reserve (FFR) System, Intravascular Ultrasound (IVUS) Systems and Optical Coherence Tomography (OCT) Systems

End Users segment is segmented into Hospitals, Surgical Centers, Cardiac Centers, and Others

Geographically, the global interventional cardiology market is sub-segmented into North America, Europe, Asia-Pacific, Middle East and Africa and South America and insights are provided for each region and major countries within the regions. 

Regional Analysis

North America region is the largest contributor to the interventional cardiology market in the forecast period 2020-2028 and the Asia-Pacific region is expected to grow with the highest CAGR during the forecast period 2020-2028.

Competitive Landscape

Key players in the global interventional cardiology market are Abiomed, Inc., ACIST Medical Systems, Inc., B. Braun Melsungen AG, Biosensors International Group, Ltd., Biotronik SE & Co. KG, Boston Scientific Corporation, C. R. Bard, Inc., Cook Medical LLC, Cordis Corporation, Edwards Lifesciences Corporation, GE Healthcare, Life Vascular Devices Biotech S.L., Biostense Webster, Inc., Medtronic Plc, Merit Medical Systems, Inc., Novacam Technologies Inc., Koninklijke Philips N.V., St. Jude Medical, Terumo Corporation, and W.L. Gore & Associates, Inc among others

Recent Developments

The companies have come up with various promotional activities in from of launch, investment, acquisition, and other, for instance:

• In 2018, Boston Scientific Corporation has announced to acquire Claret Medical, Inc. which has developed and commercialized the Sentinel Cerebral Embolic Protection System which is used for protecting the brain during certain interventional procedures.
• In 2019, Abiomed has announced the launch of Impella CP with SmartAssist, which is designed for improving patient outcomes with advanced algorithms and simplified patient management at the 2019 Society for Cardiovascular Angiography & Interventions (SCAI) Scientific Sessions.

Hence, tremendous progress has been made over the last decade and yet a lot more to come in the recent years

Reasons to Acquire

• Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors
• Gain authentic and granular data access for the interventional cardiology market so as to understand the trends and the factors involved behind changing market situations
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns

Report Scope